We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

FDA Delays Off-Label Rule Opposed By Big Pharma

Law360, New York (March 17, 2017, 7:42 PM EDT) -- Bowing to pressure from Big Pharma, the U.S. Food and Drug Administration on Friday delayed by one year a controversial new rule that endorsed a broad approach to determining whether drug and device makers are engaged in off-label promotion.

The delay to March 19, 2018 came in response to a citizen petition filed last month by Pharmaceutical Research and Manufacturers of America, the Biotechnology Innovation Organization and a drugmaker coalition called the Medical Information Working Group. The petition, which sought a stay and reconsideration, strongly criticized...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.